In addition, secreted factors can also directly inhibit the anti-tumor activity of DCs, such as TGF-β, which can inhibit antigen uptake in vitro and it was shown that inhibiting TGF-β signaling synergizes with immunotherapy in pre-clinical mouse models (15, 37, 38). Here, TGFB1 is linked to neoplasm.